Other languages Xvivo Perfusion AB

Equities

XVIVO

SE0004840718

Market Closed - Nasdaq Stockholm Other stock markets 11:29:31 2024-04-26 am EDT			5-day change	1st Jan Change
373 ^SEK	+4.63%		+17.85%	+13.20%

Apr. 24	Nordic Shares Declined Wednesday; Svenska Handelsbnkn Ser A Fell Furthest	DJ
Apr. 24	Transcript : Xvivo Perfusion AB, Q1 2024 Earnings Call, Apr 24, 2024

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

LE OPINIONI DEGLI ANALISTI DEL GIORNO : Moncler, Boreo, Fugro, STMicroelectronics, Alfen, Iberdrola, Roche, Temenos, Akzo Nobel...	Apr. 25
AVIS D'ANALYSTES DU JOUR : Kering, Carrefour, STMicroelectronics, ArgenX, Ipsen, Accor, Moncler...	Apr. 25
OPINIONES DE LOS ANALISTAS DEL DÍA : Aedas Homes, Almirall, STMicroelectronics, Enagás, Iberdrola, Roche, Temenos, Moncler...	Apr. 25
Xvivo Perfusion AB Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 24
Xvivo Perfusion AB Announces Results from Clinical Trial NIHP2019 for Heart Preservation Presented at ISHLT in Prague	Apr. 11
Les actions en mouvement : Vetoquinol et Teleperformance coulent, Vusiongroup et ID Logistics brillent	Jan. 25
Xvivo Perfusion AB Reports Earnings Results for the Full Year Ended December 31, 2023	Jan. 25
Xvivo Perfusion AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Jan. 25
Xvivo Perfusion AB Announces Results from A Australian/New Zealand Study Using Xvivo's Heart Technology Published	Nov. 03
Xvivo Perfusion AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-24
Xvivo Perfusion AB Announces Leading Acacemic Medical Center Performs First Heart Transplant in the U.S. Utilizing NIHP Technology as Part of Xvivo's Preserve Clinical Trial	23-10-23
Xvivo Perfusion AB Announces Appointment of Members of Nomination Committee	23-09-29
Xvivo Perfusion to Raise SEK440 Million from Directed Share Issue	23-09-14
Xvivo Perfusion Gets USFDA Nod on Using Donated Hearts in Heart Preservation Clinical Trial	23-07-25
US Food & Drug Administration Grants Xvivo Perfusion AB Approval to Include DCD Heartarts in IDE Clinical Trial	23-07-25
Xvivo Perfusion Closes PrimECC Trial Amid Patient Recruitment Challenges	23-07-13
Xvivo Perfusion AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-13
Xvivo Perfusion AB Announces Its Decision to Close the PrimECC(R) Study for Further Patient Inclusions - Strategic Opportunities Will Be Evaluated	23-07-12
XVIVO Perfusion AB Enters into A Strategic Collaboration with MTJ Aviation to Strengthen Organ Procurement Services in the US	23-07-10
Xvivo Announces Patient Inclusion Completed in European Clinical Trial with Heart Preservation Technology	23-05-23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Xvivo Perfusion AB

Equities

XVIVO

SE0004840718

Other languages

Filters